Drug intelligence / Profile preview

SBK008

Development stage: Unknown
Lead developer: Chengdu Shibeikang Biomedical Technology
Modality: Small Molecules
Administration: Oral

Overview

SBK008 is a small molecule therapeutic candidate under development by Chengdu Shibeikang Biotechnology for the treatment of cognitive impairment associated with mild to moderate ischemic stroke. The compound is part of a cerebrovascular pipeline that utilizes a multi-target engagement strategy, employing synergistic mechanisms to address the neurological sequelae of stroke. SBK008 is currently in Phase 2 clinical trials, representing one of the lead assets in the sponsor's cardiovascular and cerebrovascular portfolio. The specific molecular targets of SBK008 have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on SBK008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBK008.

Explore the full profile